EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS

Overview

Journal Adv Ther

Date 2023 May 31

PMID 37256536

Authors

Roland Buhl

Michael Dreher

Muriel Mattiucci-Guehlke

Rachel Emerson-Stadler

Sebastian Eckhardt

Christian Taube

Claus F Vogelmeier

Affiliations

Soon will be listed here.

Abstract

Introduction: The Global Initiative for Chronic Obstructive Lung Disease (GOLD 2023) no longer recommends a long-acting β-agonist (LABA) plus inhaled corticosteroid (ICS) combination for the treatment of chronic obstructive pulmonary disease (COPD). In patients treated with LABA/ICS, who continue to experience symptoms without frequent or severe exacerbations, GOLD now recommends switching to long-acting muscarinic antagonist (LAMA)/LABA instead of escalating to triple therapy (TT; LAMA/LABA/ICS), which previously was also a recommended option. EVELUT, a real-life, observational study, compared these two treatment strategies in terms of symptom relief and health status improvement.

Methods: Patients with symptomatic COPD at low exacerbation risk (GOLD B) were switched, at their physicians' discretion, from LABA/ICS to either fixed-dose LAMA/LABA (tiotropium/olodaterol, Respimat [Tio/Olo]) or fixed or free TT. Primary endpoints were change in modified Medical Research Council (mMRC) and COPD Assessment Test™ (CAT™) scores after 12 weeks.

Results: The safety set contained 463 patients (Tio/Olo, n = 329; TT, n = 134). In a propensity score-matched set (Tio/Olo, n = 121; TT, n = 121), improvement in mMRC score was similar in patients on Tio/Olo (-0.23; 95% confidence interval [CI] -0.11, -0.36) and TT (-0.25; 95% CI -0.13, -0.38). Improvement in total CAT score was slightly larger in patients on Tio/Olo (-3.45; 95% CI -2.45, -4.45) versus TT (-2.51; 95% CI -1.62, -3.40). In both groups, Physician's Global Evaluation scores increased, with 69-89% of patients satisfied with their treatment overall. Marginally more patients on Tio/Olo responded to treatment versus TT (Δ mMRC score ≥ 1; 25% vs. 22%; Δ CAT score ≥ 2, 68% vs. 56%).

Conclusion: In patients with symptomatic COPD at low exacerbation risk, treatment can be switched from LABA/ICS to LAMA/LABA without compromising clinical benefit, compared with escalating to LAMA/LABA/ICS. Switching from LABA/ICS to LAMA/LABA can provide symptom relief and improve health status without exposure to the risks associated with ICS.

Clinical Trial Registration: ClinicalTrials.gov: NCT03954132.

References

Miravitlles M, Auladell-Rispau A, Monteagudo M, Vazquez-Niebla J, Mohammed J, Nunez A . Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Rev. 2021; 30(160). PMC: 9488732. DOI: 10.1183/16000617.0075-2021. View

Vogelmeier C, Worth H, Buhl R, Criee C, Guckel E, Kardos P . Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study. Respir Res. 2022; 23(1):109. PMC: 9059416. DOI: 10.1186/s12931-022-02037-2. View

Kardos P, Vogelmeier C, Worth H, Buhl R, Lossi N, Mailander C . A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study. Respir Med. 2017; 124:57-64. DOI: 10.1016/j.rmed.2017.02.007. View

Singh D, Ferguson G, Bolitschek J, Gronke L, Hallmann C, Bennett N . Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015; 109(10):1312-9. DOI: 10.1016/j.rmed.2015.08.002. View

Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner C . A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT Study Protocol. Int J Chron Obstruct Pulmon Dis. 2020; 15:2601-2608. PMC: 7591229. DOI: 10.2147/COPD.S262746. View

Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G . Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015; 45(4):969-79. PMC: 4391658. DOI: 10.1183/09031936.00136014. View

Ciciliani A, Langguth P, Wachtel H . In vitro dose comparison of Respimat inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2017; 12:1565-1577. PMC: 5457178. DOI: 10.2147/COPD.S115886. View

Huang W, Chen C, Liao W, Wu B, Chen W, Tu C . A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2021; 16:1555-1568. PMC: 8184143. DOI: 10.2147/COPD.S308911. View

van der Palen J, Moeskops-van Beurden W, Dawson C, James W, Preece A, Midwinter D . A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2018; 13:2515-2523. PMC: 6110160. DOI: 10.2147/COPD.S169060. View

10.

Ciciliani A, Denny M, Langguth P, Voshaar T, Wachtel H . Lung Deposition Using the Respimat Soft Mist™ Inhaler Mono and Fixed-Dose Combination Therapies: An / Analysis. COPD. 2020; 18(1):91-100. DOI: 10.1080/15412555.2020.1853091. View

11.

Taube C, Bayer V, Zehendner C, Valipour A . Assessment of Patient Experiences with Respimat in Everyday Clinical Practice. Pulm Ther. 2020; 6(2):371-380. PMC: 7671953. DOI: 10.1007/s41030-020-00127-4. View

12.

Dreher M, Price D, Gardev A, Peeters P, Arora S, van der Sar-van der Brugge S . Patient perceptions of the re-usable Respimatt Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study. Chron Respir Dis. 2021; 18:1479973120986228. PMC: 7868496. DOI: 10.1177/1479973120986228. View

13.

Singh D, Wedzicha J, Siddiqui S, de la Hoz A, Xue W, Magnussen H . Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020; 21(1):240. PMC: 7499955. DOI: 10.1186/s12931-020-01482-1. View

14.

Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K . Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017; 49(5). PMC: 5460642. DOI: 10.1183/13993003.01446-2016. View

15.

Worth H, Buhl R, Criee C, Kardos P, Guckel E, Vogelmeier C . In 'real world' patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations. Respir Res. 2023; 24(1):2. PMC: 9814325. DOI: 10.1186/s12931-023-02311-x. View

16.

Lopez-Campos J, Calero C, Quintana-Gallego E . Symptom variability in COPD: a narrative review. Int J Chron Obstruct Pulmon Dis. 2013; 8:231-8. PMC: 3653762. DOI: 10.2147/COPD.S42866. View

17.

Zhang S, King D, Rosen V, Ismaila A . Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review. Int J Chron Obstruct Pulmon Dis. 2020; 15:417-438. PMC: 7049753. DOI: 10.2147/COPD.S234823. View

18.

Gillissen A, Marseille A, Skowasch D, Ritz J, Mattiucci-Guehlke M, Pabst S . Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study. ERJ Open Res. 2021; 7(3). PMC: 8419313. DOI: 10.1183/23120541.00004-2021. View

19.

Chalmers J, Laska I, Franssen F, Janssens W, Pavord I, Rigau D . Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020; 55(6). DOI: 10.1183/13993003.00351-2020. View

20.

Steinmetz K, Abenhardt B, Pabst S, Hansel M, Kondla A, Bayer V . Assessment of physical functioning and handling of tiotropium/olodaterol Respimat in patients with COPD in a real-world clinical setting. Int J Chron Obstruct Pulmon Dis. 2019; 14:1441-1453. PMC: 6618035. DOI: 10.2147/COPD.S195852. View